Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more
Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...
Zacks.com on MSN3d
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback